Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart While Combating Cancer

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2024 Jul 23

PMID 39042344

Authors

Amit Manhas

Dipti Tripathi

Dilip Thomas

Nazish Sayed

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review explores the cardiovascular toxicity associated with cancer therapies, emphasizing the significance of the growing field of cardio-oncology. It aims to elucidate the mechanisms of cardiotoxicity due to radiotherapy, chemotherapy, and targeted therapies, and to discuss the advancements in human induced pluripotent stem cell technology (hiPSC) for predictive disease modeling.

Recent Findings: Recent studies have identified several chemotherapeutic agents, including anthracyclines and kinase inhibitors, that significantly increase cardiovascular risks. Advances in hiPSC technology have enabled the differentiation of these cells into cardiovascular lineages, facilitating more accurate modeling of drug-induced cardiotoxicity. Moreover, integrating hiPSCs into clinical trials holds promise for personalized cardiotoxicity assessments, potentially enhancing patient-specific therapeutic strategies. Cardio-oncology bridges oncology and cardiology to mitigate the cardiovascular side-effects of cancer treatments. Despite advancements in predictive models using hiPSCs, challenges persist in accurately replicating adult heart tissue and ensuring reproducibility. Ongoing research is essential for developing personalized therapies that balance effective cancer treatment with minimal cardiovascular harm.

References

Miller K, Nogueira L, Devasia T, Mariotto A, Yabroff K, Jemal A . Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022; 72(5):409-436. DOI: 10.3322/caac.21731. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Siegel R, Giaquinto A, Jemal A . Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1):12-49. DOI: 10.3322/caac.21820. View

Mariotto A, Noone A, Howlader N, Cho H, Keel G, Garshell J . Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014; 2014(49):145-86. PMC: 4829054. DOI: 10.1093/jncimonographs/lgu024. View

Miller K, Nogueira L, Mariotto A, Rowland J, Yabroff K, Alfano C . Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69(5):363-385. DOI: 10.3322/caac.21565. View

Gegechkori N, Haines L, Lin J . Long-Term and Latent Side Effects of Specific Cancer Types. Med Clin North Am. 2017; 101(6):1053-1073. PMC: 5777532. DOI: 10.1016/j.mcna.2017.06.003. View

Armenian S, Xu L, Ky B, Sun C, Farol L, Pal S . Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016; 34(10):1122-30. PMC: 7357493. DOI: 10.1200/JCO.2015.64.0409. View

Bates J, Howell R, Liu Q, Yasui Y, Mulrooney D, Dhakal S . Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study. J Clin Oncol. 2019; 37(13):1090-1101. PMC: 6494356. DOI: 10.1200/JCO.18.01764. View

10.

Strongman H, Gadd S, Matthews A, Mansfield K, Stanway S, Lyon A . Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019; 394(10203):1041-1054. PMC: 6857444. DOI: 10.1016/S0140-6736(19)31674-5. View

11.

Armstrong G, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson M . Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014; 32(12):1218-27. PMC: 3986385. DOI: 10.1200/JCO.2013.51.1055. View

12.

Hudson M, Ness K, Gurney J, Mulrooney D, Chemaitilly W, Krull K . Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309(22):2371-2381. PMC: 3771083. DOI: 10.1001/jama.2013.6296. View

13.

Shakir D, Rasul K . Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management. J Clin Med Res. 2012; 1(1):8-12. PMC: 3318862. DOI: 10.4021/jocmr2009.02.1225. View

14.

Hayek E, Speakman E, Rehmus E . Acute doxorubicin cardiotoxicity. N Engl J Med. 2005; 352(23):2456-7. DOI: 10.1056/NEJM200506093522321. View

15.

Chatterjee K, Zhang J, Honbo N, Karliner J . Doxorubicin cardiomyopathy. Cardiology. 2009; 115(2):155-62. PMC: 2848530. DOI: 10.1159/000265166. View

16.

Zhao L, Zhang B . Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Sci Rep. 2017; 7:44735. PMC: 5353581. DOI: 10.1038/srep44735. View

17.

Lamore S, Kohnken R, Peters M, Kolaja K . Cardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches. Chem Res Toxicol. 2019; 33(1):125-136. DOI: 10.1021/acs.chemrestox.9b00387. View

18.

Kondapalli L, Hsia J, Miller R, Flaig T, Bonaca M . Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded Outcomes. JACC CardioOncol. 2023; 4(5):649-656. PMC: 9830208. DOI: 10.1016/j.jaccao.2022.09.003. View

19.

Herman E, Ferrans V . Preclinical animal models of cardiac protection from anthracycline-induced cardiotoxicity. Semin Oncol. 1998; 25(4 Suppl 10):15-21. View

20.

Csobonyeiova M, Polak S, Danisovic L . Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells. Can J Physiol Pharmacol. 2016; 94(7):687-94. DOI: 10.1139/cjpp-2015-0459. View